Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00051
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
TAT
|
|||||
| Structure |
|
|||||
| Sequence |
GRKKRRQRRRPPQ
|
|||||
| Peptide Type |
Linear
|
|||||
| Peptide Half Life Period |
1.7 h
|
|||||
| PDC Transmembrane Types | Cell-penetrating peptides (CPPs) | |||||
| Formula |
C70H131N35O16
|
|||||
| Isosmiles |
[H]NCCCC[C@H](NC(=O)[C@H](CCC/N=C(\N)N[H])NC(=O)CN[H])C(=O)N[C@@H](CCCCN[H])C(=O)N[C@@H](CCC/N=C(\N)N[H])C(=O)N[C@@H](CCC/N=C(\N)N[H])C(=O)N[C@@H](CCC(=O)N[H])C(=O)N[C@@H](CCC/N=C(\N)N[H])C(=O)N[C@@H](CCC/N=C(\N)N[H])C(=O)N[C@@H](CCC/N=C(\N)N[H])C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N[H])C(=O)O
|
|||||
| InChI |
InChI=1S/C70H131N35O16/c71-27-3-1-13-39(95-53(109)38(94-52(108)37-73)15-5-29-88-65(76)77)54(110)96-40(14-2-4-28-72)55(111)97-41(16-6-30-89-66(78)79)56(112)98-43(18-8-32-91-68(82)83)58(114)101-45(23-25-50(74)106)60(116)100-42(17-7-31-90-67(80)81)57(113)99-44(19-9-33-92-69(84)85)59(115)102-46(20-10-34-93-70(86)87)62(118)105-36-12-22-49(105)63(119)104-35-11-21-48(104)61(117)103-47(64(120)121)24-26-51(75)107/h38-49H,1-37,71-73H2,(H2,74,106)(H2,75,107)(H,94,108)(H,95,109)(H,96,110)(H,97,111)(H,98,112)(H,99,113)(H,100,116)(H,101,114)(H,102,115)(H,103,117)(H,120,121)(H4,76,77,88)(H4,78,79,89)(H4,80,81,90)(H4,82,83,91)(H4,84,85,92)(H4,86,87,93)/t38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
|
|||||
| InChIKey |
RAIPPQLNSCSOOW-XNHKUAGSSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1719.047
|
Polar area
|
919.56
|
||
|
Complexity
|
1718.051303
|
xlogp Value
|
-13.0297
|
|||
|
Heavy Count
|
121
|
Rot Bonds
|
64
|
|||
|
Hbond acc
|
24
|
Hbond Donor
|
28
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
Cq-C4-TAT [Investigative]
Obtained from the Model Organism Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Malaria | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10 µM | |||
| MOA of PDC |
The significant increase in the hemolytic activity of TP10 upon conjugation to the 4-aminoquinoline suggests that drug cargo prevents an otherwise active CPP carrier from exerting the desired cell penetrating/antiplasmodial action safely, as it produces conjugates that exert membranolytic activity.
|
||||
| Description |
Only three of the Cq-C4-CPP conjugates, namely, 5a, 5b, and 5g, displayed IC50 values below 10 μM, with TP10- and Transportan-derived conjugates 5a (IC50 = 1.52 μM) and 5b (IC50 = 5.20 μM) being the most active.
|
||||
| In Vivo Model | Plasmodium falciparum W2. | ||||
References